ABO 2102 / Suzhou Abogen Biosci - LARVOL DELTA

Study of ABO2102 in KRAS-Mutated Solid Tumors (clinicaltrials.gov) - P1 | N=101 | Recruiting | Sponsor: Suzhou Abogen Biosciences Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • IO biomarker • Oncology • Solid Tumor • KRAS

Study of ABO2102 in KRAS-Mutated Solid Tumors (clinicaltrials.gov) - P1 | N=101 | Not yet recruiting | Sponsor: Suzhou Abogen Biosciences Co., Ltd.

IO biomarker • New P1 trial • Oncology • Solid Tumor • KRAS

Study of KRAS Neoantigen mRNA Vaccine (ABO2102) in Patients With KRAS -Mutated Advanced Pancreatic Cancer (clinicaltrials.gov) - P1 | N=56 | Recruiting | Sponsor: Ruijin Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor

Study of KRAS Neoantigen mRNA Vaccine (ABO2102) in Patients With KRAS -Mutated Advanced Pancreatic Cancer (clinicaltrials.gov) - P1 | N=56 | Not yet recruiting | Sponsor: Ruijin Hospital

IO biomarker • Metastases • New P1 trial • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor